Company Filing History:
Years Active: 2024
Title: George S. Laszlo: Innovator in Anti-CD33 Antibodies
Introduction
George S. Laszlo is a prominent inventor based in Seattle, WA, known for his significant contributions to the field of immunology. He has developed innovative therapeutic approaches targeting CD33-related disorders through his research and patents. His work has the potential to enhance treatment efficacy for various diseases.
Latest Patents
George S. Laszlo holds a patent for "Anti-CD33 antibodies and uses thereof." This patent describes anti-CD33 antibodies that can bind within the V-set Ig-like domain or the C2-set Ig-like domain of CD33. The antibodies are designed to target specific epitopes on the C2-set Ig-like domain, providing a 'pan-binding' site that allows for effective binding regardless of the presence of the V-set domain. This innovation opens new avenues for therapeutic interventions against CD33-related disorders. The patent also includes methods of use and describes various molecules that incorporate binding-competent domains from the anti-CD33 antibodies, such as scFvs, bi-specific antibody molecules, chimeric antigen receptors, and immunoconjugates.
Career Highlights
George S. Laszlo is affiliated with the Fred Hutchinson Cancer Center, where he conducts groundbreaking research in cancer immunotherapy. His work focuses on developing novel therapeutic targets that can significantly improve treatment outcomes for patients suffering from CD33-related conditions. With a patent portfolio that includes 1 patent, he has established himself as a key figure in the field of antibody research.
Collaborations
George has collaborated with notable colleagues, including Roland B. Walter and Christopher Mehlin, to advance the understanding and application of anti-CD33 antibodies in clinical settings.
Conclusion
George S. Laszlo's innovative work in the development of anti-CD33 antibodies represents a significant advancement in therapeutic strategies for treating CD33-related disorders. His contributions continue to influence the field of immunology and cancer treatment.